Modi’s India takes on Trump more openly, from ‘terrorism’ to tariffs

India has publicly hardened its stance toward the Trump administration as a proposed US tariff of up to 100% on countries purchasing Russian oil, including India, is due in less than a month. The dispute threatens a bilateral relationship underpinned by $149.1B in 2025 goods trade, in which India holds a $58.4B surplus, while unresolved agricultural-market access remains a key obstacle to a trade agreement. Frictions over US engagement with Pakistan, Trump’s claims over the India-Pakistan ceasefire, and tighter H-1B migration policies are adding geopolitical and domestic political pressure on Prime Minister Narendra Modi.

Analysis

The investable channel is not diplomatic rhetoric but whether Washington turns secondary-sanctions authority into enforceable country-level tariffs. India’s equity index has relatively limited direct goods-export sensitivity versus North Asian exporters, but INDA/SMIN would still face a risk-premium shock: foreign flows are particularly vulnerable when trade uncertainty coincides with domestic-election positioning and a weaker rupee. The near-term losers are India’s labor-intensive exporters and US-facing generic-drug, textile, jewelry and auto-component suppliers; IT services such as INFY and WIT are less tariff-exposed but could suffer if H-1B restrictions impair onsite staffing economics and raise delivery costs.

A more consequential second-order effect is energy. A forced reduction in Russian crude purchases removes a discounted feedstock advantage for Indian refiners, potentially compressing gross refining margins at IOC, BPCL and HPCL while raising domestic fuel-subsidy or retail-price intervention risk. Conversely, reduced Indian demand for Russian barrels would widen Urals discounts and benefit China-based refiners; it is not automatically bullish for global oil because displaced barrels can still clear through other buyers. For US assets, higher input costs for Indian-origin imports would be modestly inflationary but most material for low-margin retailers and generic-drug procurement chains rather than broad CPI.

Consensus is likely over-discounting an irreversible strategic break. New Delhi has strong incentives to preserve market access and capital inflows, while Washington’s China-containment strategy limits its willingness to permanently alienate India; a negotiated carve-out or delayed implementation could trigger a sharp relief move in Indian risk assets within 1-3 months. The thesis fails if tariff implementation is broad, legally durable and paired with enforcement against Russian-oil-linked refiners; monitor announced product exemptions, India’s Russian crude import volumes, INR stability and revisions to US-facing export guidance.

Over 6-18 months, recurring policy volatility should accelerate India’s diversification toward Gulf, EU and Asian markets and encourage more localized US production/service delivery. That is structurally favorable to globally diversified Indian IT firms and US/Indian manufacturers able to shift final assembly, but unfavorable to smaller exporters that lack balance-sheet capacity to absorb duty costs or relocate supply chains.

Key Decisions for Investors

• Do not chase a broad INDA short on rhetoric alone; use a 1-3 month tactical long INDA only after evidence of a tariff delay, sector exemption, or trade-agreement timetable. A 5-7% relief rally is plausible on de-escalation, while implemented broad tariffs with INR weakness would invalidate the setup.
• Prefer a defensive India pair: long INFY versus short INDA for the next 1-3 months. INFY’s revenue exposure is primarily services rather than merchandise trade, while INDA carries greater bank, industrial and domestic-risk-premium exposure; exit if US mobility restrictions cause a material deterioration in INFY’s onsite wage utilization or FY guidance.
• Avoid or underweight Indian state refiners IOC, BPCL and HPCL until Russian-crude sourcing and refining-margin sensitivity are clarified. Re-enter only if Urals discounts remain sufficient to offset any compliance costs; a sustained narrowing of the Urals-Brent discount is the key earnings-risk trigger.
• Watch US-listed generic-pharma and retail supply-chain exposures rather than taking a blanket US inflation trade. If tariffs explicitly include pharmaceuticals, favor relative longs in domestic-oriented branded pharma over India-dependent generic procurement; absent product-level tariff schedules, this remains an alert rather than a position.